# A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants

> **NCT06663436** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 200 (actual)

## Conditions studied

- Diarrhoea

## Interventions

- **BIOLOGICAL:** altSonflex1-2-3 Dose A
- **BIOLOGICAL:** altSonflex1-2-3 Dose B
- **BIOLOGICAL:** altSonflex1-2-3 Dose C
- **BIOLOGICAL:** TYPHIBEV
- **COMBINATION_PRODUCT:** Infanrix hexa
- **BIOLOGICAL:** MR-VAC

## Key facts

- **NCT ID:** NCT06663436
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-13
- **Primary completion:** 2025-10-21
- **Final completion:** 2025-10-21
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06663436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06663436, "A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06663436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*